MAR

Press Release
Active Biotech announces a fully secured rights issue of approximately SEK 70 million
2025-10-17
Regulatory
Press Release
Active Biotech reports positive top-line results from the LION study on ocular absorption and distribution of laquinimod in the eye
2025-05-05
Regulatory
Press Release
Active Biotech raises SEK 43.4 million in substantially oversubscribed rights issue including exercise of over-allotment option
2024-11-18
Regulatory
Press Release
Active Biotech announces a rights issue of SEK 35 million
2024-09-23
Regulatory
Press Release
Active Biotech reports intriguing intraocular concentrations achieved in a clinical biodistribution study of laquinimod eye drops
2024-09-10
Regulatory
Press Release
Active Biotech provides update on the clinical phase Ib/IIa study with tasquinimod in relapsed refractory multiple myeloma
2024-07-15
Regulatory
Press Release
Clinical activity and safety of naptumomab and docetaxel to be presented at ASCO 2024
2024-05-28
Regulatory
Press Release
Active Biotech acquires exclusive rights to patents of tasquinimod in combination therapy
2024-05-22
Regulatory
Press Release
Active Biotech announces outcome of the Company’s rights issue
2023-12-06
Regulatory
Press Release
Active Biotech announces a rights issue of approximately SEK 51 million
2023-11-09
Regulatory